Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension

Hypertension

Volumn 27, Issue 4, 1996, Pages 906-913

  Pidgeon, Grant B ^a   Richards, A Mark ^a   Nicholls, M Gary ^a   Espiner, Eric A ^a   Yandle, Tim G ^a   Frampton, Chris ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

catecholamines; cyclic GMP; hypertension, essential; natriuresis; natriuretic peptides; renin angiotensin system

Indexed keywords

ADRENALIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CYCLIC GMP; HYDROCORTISONE; NORADRENALIN; RENIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ESSENTIAL HYPERTENSION; HEART FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; MALE; NATRIURESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECOND MESSENGER; SINGLE BLIND PROCEDURE;

EID: 0029911630     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.4.906     Document Type: Article

References (36)

1. Sagnella GA, Markandu ND, Shore AC, MacGregor GA. Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet. 1986;1:179-181.
2. Montorsi P, Tonolo G, Polonia J, Hepburn D, Richards AM. Correlates of plasma atrial natriuretic factor in health and hypertension. Hypertension. 1987;10:570-576.
3. Hollister AS, Inagami T. Atrial natriuretic factor and hypertension: a review and metaanalysis. Am J Hypertens. 1991;4:850-865.
4. Richards AM, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Joyce SL, Cullens MM. Effects of α-human atrial natriuretic peptide in essential hypertension. Hypertension. 1985;7:812-817.
5. Weidmann P, Gnadinger MP, Ziswiler HR, Shaw S, Bachmann C, Rascher W, Uehlinger DE, Hasler L, Reubi FC. Cardiovascular, endocrine and renal effects of atrial natriuretic peptide in essential hypertension. J Hypertens. 1986;4(suppl 2):S71-S83.
6. Tonolo G, Richards AM, Manunta P, Pazzola A, Pala F, Glorioso N. Low dose infusion of atrial natriuretic factor in mild essential hypertension. Circulation. 1989;80:893-902.
7. Richards AM, Espiner EA, Ikram H, Yandle TG. Atrial natriuretic factor in hypertension: bioactivity at normal plasma levels. Hypertension. 1989;14:261-268.
8. Janssen WMT, de Zeeuw D, van der Hem GK, de Jong PE. Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans. Hypertension, 1989;13:640-646.
9. Sudoh T, Kangawa K, Minamino N, Malsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81.
10. McGregor A, Richards M, Espiner E, Yandle T, Ikram H. Brain natriuretic peptide administered to man: actions and metabolism. J Clin Endocrinol Metab. 1990;70:1103-1107.
11. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96.
12. Cheung BMY, Dickerson JEC, Ashby MJ, Brown MJ, Brown J. Effects of physiological increments in human α-atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects. Clin Sci. 1994;86:723-730.
13. Cargill RI, Struthers AD, Lipworth BJ. Comparative effects of atrial natriuretic peptide and brain natriuretic peptide on the aldosterone and pressor responses to angiotensin II in man. Clin Sci. 1995;88:81-86.
14. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
15. Richards AM, Crozier IG, Holmes SJ, Espiner EA, Yandle TG, Frampton C. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J Hypertens. 1993;11:163-170.
16. La Villa G, Bisi G, Lazzeri C, Fronzaroli C, Stefani L, Barletta G, Del Bene R, Messeri G, Strazyulla G, Franchi F. Cardiovascular effects of brain natriuretic peptide in essential hypertension. Hypertension. 1995;25:1053-1057.
17. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci. 1986;38:1827-1833.
18. Florkowski CM, Richards AM, Espiner EA, Yandle TG, Frampton C. Renal, endocrine, and haemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol. 1994;266:R1244-R1250.
19. Hunt PJ, Espiner EA, Richards AM, Yandle TG, Frampton C, Nicholls MG. Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am J Physiol. In press.
20. Kohno M, Horio T, Yokokawa K, Murakawa K-I, Yasunari K, Akioka K, Tahara A, Toda I, Takeuchi K, Kurihara N, Takeda T. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 1992;92:29-34.
21. Mukoyama M, Nakao K, Obata K, Jougasaki M, Yoshimura M, Morita E, Hosoda K, Suga S-I, Ogawa Y, Yasue H, Imura H. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun. 1991;180:431-436.
22. Burnett JC, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147.
23. Morwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993;341:1109-1113.
24. Varley H, ed. Practical Clinical Chemistry. 4th ed. London, UK: Heinemann; 1967:175-179.
25. Yandle T, Espiner E, Nicholls M, Duff H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endociinol Metab. 1986;61:71-78.
26. Yandle T, Richards A, Gilbert A, Fisher S, Holmes S, Espiner E. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993;76:832-838.
27. Steiner A, Parker C, Kipnis D. Radioimmunoassay for cyclic nucleotides. J Biol Chem. 1972;247:1106-1113.
28. Dunn P, Espiner E. Outpatient screening tests for primary aldosteronism. Aust N Z J Med. 1976;6:131-135.
29. Lun S, Espiner E, Nicholls M, Yandle T. A direct radioimmunoassay for aldosterone in plasma. Clin Chem. 1983;29:268-271.
30. Goldstein DS, Feuerstein G, Izzo JL, Kopin IJ, Keiser HR. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epincphrine in man. Life Sci. 1981;28:467-475.
31. Wilkinson L. SYSTAT. The System for Statistics. Evanston, Ill: Systat Inc; 1990.
32. Richards AM, Tonolo G, Montorsi P, Finlayson J, Fraser R, Inglis G, Towrie A, Morton JJ. Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man. J Clin Endocrinol Metab. 1988;66:465-472.
33. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kumbayashi Y, Inouye K, Imura H. Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, ANP and BNP. J Clin Invest. 1991;87:1402-1412.
34. Kenny A, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291:83-88.
35. Sosa RE, Volpe M, Marion DN, Atlas SA, Laragh JH, Vaughan ED, Maack T. Relationship between renal, hemodynamic and natriuretic effects of atrial natriuretic factor. Am J Physiol. 1986;250:F520-F524.
36. Davis CL, Briggs JP. Effect of reduction in renal artery pressure on atrial natriuretic peptide-induced natriuresis. Am J Physiol. 1987;252:F146-F153.